Anti-nme antibody

Abstract

The present application discloses anti-NME antibodies and their use in treating or preventing diseases.

1 . A method of treating or preventing cancer in a subject, comprising administering to the subject an antibody made against a member of the NME family. 
     
     
         2 . The method according to  claim 1 , wherein the NME family is NME7 family. 
     
     
         3 . The method according to  claim 2 , wherein the antibody binds to NME7. 
     
     
         4 . The method according to  claim 2 , wherein the antibody binds to NME7-AB or NME-AB-like protein. 
     
     
         5 . The method according to  claim 2 , wherein the antibody binds to NME7-X1. 
     
     
         6 . The method according to  claim 1 , wherein the antibody inhibits binding between NME7 and its cognate binding partner. 
     
     
         7 . The method according to  claim 6 , wherein the cognate binding partner is MUC1*. 
     
     
         8 . The method according to  claim 6 , wherein the cognate binding partner is PSMGFR portion of the MUC1* extracellular domain. 
     
     
         9 . The method according to  claim 1 , wherein the antibody is generated or selected for its ability to bind to a peptide selected from those listed in  FIGS. 16-19  (SEQ ID NOS:88 to 145). 
     
     
         10 . The method according to  claim 9 , wherein the peptide is selected from those listed in  FIG. 19  (SEQ ID NOS:141 to 145). 
     
     
         11 . The method according to  claim 9 , wherein the peptide comprises a peptide, which is highly homologous to, or to which is added or subtracted up to 7 amino acid residues at the N-terminus or C-terminus, of the peptides listed in  FIGS. 16-19  (SEQ ID NOS:88 to 145). 
     
     
         12 . The method according to  claim 1 , wherein the antibody is selected for its ability to bind to NME7-AB or NME7-X1 but not to NME1. 
     
     
         13 . The method according to  claim 1 , wherein the antibody is polyclonal, monoclonal, bivalent, monovalent, bispecific, an antibody fragment containing the variable region, or an antibody mimic. 
     
     
         14 . The method according to  claim 1 , wherein the antibody is human or humanized. 
     
     
         15 . The method according to  claim 1 , wherein the antibody is a single chain scFv. 
     
     
         16 .- 24 . (canceled) 
     
     
         25 . A chimeric antigen receptor (CAR), for the treatment or prevention of cancer wherein the targeting extracellular portion of the CAR comprises at least a peptide fragment of a member of the NME family. 
     
     
         26 . The chimeric antigen receptor according to  claim 25 , wherein the NME family is NME7 family. 
     
     
         27 . The chimeric antigen receptor according to  claim 26 , wherein the member of the NME7 family is NME7. 
     
     
         28 . The chimeric antigen receptor according to  claim 26 , wherein the member of the NME7 family is NME7-AB or NME-AB-like protein. 
     
     
         29 . The chimeric antigen receptor according to  claim 26 , wherein the member of the NME7 family is NME7-X1. 
     
     
         30 .- 78 . (canceled)